Loading...
NPI 1033650866 · Irving, TX · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Firstox Laboratories, LLC is a clinical medical laboratory provider located in Irving, Texas. This profile covers 37 Medicare and 70 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Firstox Laboratories, LLC |
| Address | 4850 Plaza Dr |
| City | Irving |
| State | TX |
| ZIP | 75063 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | March 13, 2017 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $1.3M |
| Medicare | $241K |
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
37 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | 74,700 | $1 | $74.7K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 240 | $190 | $46.8K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 900 | $30 | $30.7K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 360 | $60 | $22.1K |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 200 | $70 | $13.5K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 80 | $110 | $8.4K |
| 36415 | In this procedure, the provider inserts a needle into a vein to collect a blood sample. | 970 | $10 | $4.9K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 430 | $10 | $4.3K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 460 | $10 | $3.7K |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 190 | $20 | $3.1K |
Showing 1–10 of 37
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 37 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
37 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 87798 | 144 | 300 | 790 | $30 | $265.1K |
| 87801 | 50 | 120 | 170 | $70 | $86.5K |
| P9603 | 9 | 30 | 26,220 | $1 | $73.2K |
| 87481 | 190 | 270 | 150 | $30 | $68.8K |
| G0482 | 77 | 200 | 150 | $190 | $54K |
| G0480 | 76 | 140 | 80 | $110 | $38.8K |
| 83970 | 205 | 240 | 40 | $40 | $31.2K |
| 87640 | 126 | 250 | 70 | $30 | $25.9K |
| 87653 | 118 | 230 | 70 | $30 | $24K |
| 80307 | 125 | 460 | 170 | $60 | $23.7K |
Showing 1–10 of 37
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
70 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 8,430 | $70 | $590K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 19,530 | $20 | $390.5K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 5,800 | $20 | $139.1K |
| 0054U | This is a Proprietary Laboratory Analyses (PLA) code, meaning that the code applies to only one unique lab test made by a specific manufacturer or performed by a specific lab. Report code 0054U for… | 2,180 | $50 | $109.2K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1,980 | $10 | $27.8K |
| 80171 | The lab analyst measures the amount of gabapentin in the blood, serum, or plasma. Gabapentin is a drug that the provider uses to treat certain types of seizures. | 2,640 | $10 | $15.8K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 330 | $40 | $13.7K |
| 80346 | The lab analyst measures the amount of or detects the presence of one to twelve benzodiazepines, which are tranquilizers, in a patient specimen. | 1,700 | $1 | $5.1K |
| 80362 | The lab analyst measures the amount of or detects the presence of one or two opioids and opiate analogs, narcotic analgesics that depress the central nervous system, in the specimen. | 2,030 | $1 | $4.1K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 290 | $10 | $3.8K |
Showing 1–10 of 70
How this provider's Medicaid billing volume and revenue compare to other Texas providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Texas median
70 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 54 | 100 | 470 | $50 | $319.1K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 96 | 240 | 420 | $30 | $296.8K |
| 87661 | The lab analyst performs a test for Trichomonas vaginalis using nucleic acid amplified probe technique. | 136 | 150 | 320 | $20 | $184K |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 54 | 110 | 360 | $40 | $174.9K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 159 | 260 | 640 | $20 | $137.2K |
| 87507 | The lab analyst performs a test to detect 12 to 25 types or subtypes of a pathogen, such as Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia, that affects the gastrointestinal… | 18 | 20 | 90 | $120 | $132K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 11 | 70 | 200 | $50 | $124.9K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 7 | 350 | 510 | $30 | $114.1K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 8 | 130 | 150 | $30 | $111.8K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 4 | 80 | 230 | $50 | $109K |
Showing 1–10 of 70
Other providers in the same ZIP code as Firstox Laboratories, LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Quest Diagnostics Clinical Laboratories Inc | TX | Clinical Medical Laboratory | $46.7M | $276.8M |
| Accredo Health Group Inc | TX | Pharmacy | $0 | $27.7M |
| Andrew Lee | TX | Radiation Oncology Physician | $2.2M | $0 |
| Jared Sturgeon | TX | Radiation Oncology Physician | $2.1M | $0 |
| Victor Mangona | TX | Radiation Oncology Physician | $1.6M | $0 |
| Carenexa, LLC | TX | Clinical Medical Laboratory | $1.1M | $15K |
| David Hull | TX | Anatomic Pathology & Clinical Pathology Physician | $1.1M | $10.1K |
| Biostat Imaging | TX | Portable X-ray and/or Other Portable Diagnostic Imaging Supplier | $852.9K | $179.1K |
| Daniel Suez | TX | Allergy & Immunology Physician | $697.4K | $0 |
| Thomas Salmon | TX | Neurology Physician | $591.8K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.